Target Pipelines

Subscribe to
our newsletters!

Showing 41–56 of 56 results

  • June of 2019
    This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.
     50.00
  • June of 2019
    This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.
     50.00
  • June of 2019
     150.00
  • June of 2019
    This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC)
     50.00
  • May of 2019
    This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)
     150.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of Tyk2 in development for treatment of inflammatory diseases.
     125.00
  • April of 2019
    This report provides an overview of small molecule inhibitors of NLRP3 in development for treatment of chronic inflammatory diseases.
     75.00
  • April of 2019
    This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.
     50.00
  • April of 2019
    This report provides an overview of therapeutic proteins in development for treatment of arginine-dependent tumors or for enzyme replacement therapy.
     75.00
  • March of 2019
    This Target Pipeline List provides an overview of biologic and chemical entities on the market or in development for treatment of hyperuricemia associated with gout or tumor lysis
     150.00
  • February of 2019
    This report provides an overview of isolated and recombinant asparaginase enzymes on the market or in development for treatment of leukemia and solid tumors.
     100.00
  • January of 2019
    This Target Pipeline List provides an overview of biologic and small molecule approaches to raise high density lipoprotein (HDL) for reduction of recurrent cardiovascular events.
     100.00
  • December of 2018
    This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
     75.00
  • January of 2019
    This Target Pipeline List provides an overview of agonist antibodies and fusion proteins targeting death receptor 4 and/or 5 in development for treatment of cancer.
     100.00
  • January of 2019
    This Target Pipeline List provides a pipeline overview of tau imaging agents in development for diagnosis of tauopathies and measurement of tau-targeted treatment effects
     50.00
  • January of 2019
    This Target Pipeline List provides a pipeline overview of EP4 receptor antagonists in development for treatment of cancer
     50.00